Equity - Additional Information (Details)			3 Months Ended					9 Months Ended		12 Months Ended
	May 24, 2021 shares	May 23, 2021	Sep. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares	Sep. 30, 2020 USD ($) shares	Mar. 31, 2020 USD ($) shares	Sep. 30, 2021 USD ($) D $ / shares shares	Sep. 30, 2020 USD ($) shares	Dec. 31, 2020 $ / shares shares	Jul. 23, 2021 shares
Stockholders Equity [Line Items]
Common stock, shares authorized			500,000,000					500,000,000		500,000,000
Common stock, par value | $ / shares			$ 0.001					$ 0.001		$ 0.001
Merger and PIPE Financing shares - common stock			511,065
Issuance of common stock for exercise of warrants and Unit Purchase Options | $			$ 47,319,504					$ 47,319,504
Contingently issuable Earnout Shares Excluded from EPS computation			185,472
Common stock issued for consulting services (in shares)			634,045					834,045
Non-cash consulting expense | $			$ 7,925,511					$ 12,775,511
Common stock issued | $			1,134,816	$ 1,562,272	$ 6,927,086	$ 1,412,067	$ 177,025
Proceeds from issuance of common stock | $								9,623,899	$ 1,589,103
Loss on conversion of convertible notes payable | $									$ 306,641
Common stock issued to settle note conversion (in shares)									1,138,199
Awarded to employees as bonus for services provided					210,800
Compensation expenses | $			$ 1,559,825			190,750		6,214,853	$ 373,018
Loss on settlement of accounts payable | $								$ (120,810)
Preferred stock, shares authorized			50,000,000					50,000,000		50,000,000
Preferred stock, shares issued			0					0		0
Preferred stock, par value | $ / shares			$ 0.001					$ 0.001		$ 0.001
Number of shares outstanding			0					0		0
Warrant issued			2,863,637	3,586,250	3,329,812
Warrant, exercise price per share | $ / shares			$ 9.09	$ 6.63	$ 1.78			$ 9.09		$ 1.09
Proceeds from exercise of warrant | $								$ 16,699,489
Number of shares issued upon exercise of warrants | $					$ 7,500,018
Net impact to additional paid-in capital | $					$ 60,851,779
Number of outstanding warrants			9,305,790	8,495,316	4,909,066			9,305,790		3,075,470
Change in fair value of the warrants | $								$ (822,539)
Number of units outstanding			600,000					600,000			600,000
Price per unit | $ / shares			$ 10.00					$ 10.00
Aggregate exercise price | $			$ 6,000,000					$ 6,000,000
Number of shares per unit								1
Number of shares per right								1
Unit expiration term								5 years
Demand right term								5 years
Piggy back right term								7 years
Fractional shares issued upon conversion of rights								0
Unamortized compensation costs | $			$ 32,644,383					$ 32,644,383
Substitute Warrants
Stockholders Equity [Line Items]
Warrant, exercise price per share | $ / shares			$ 2.45					$ 2.45
Warrants exercised			4,909,066					4,909,066
Public Warrants
Stockholders Equity [Line Items]
Warrant, exercise price per share | $ / shares			$ 11.50					$ 11.50
Warrants exercised			1,144					1,144
Gross proceeds from exercise of warrants | $			$ 13,156
Number of outstanding warrants			3,450,000					3,450,000
Number of shares per warrant			1					1
Warrants expiration term			5 years					5 years
Redemption price per warrant (in dollars per share) | $ / shares								$ 0.01
Minimum threshold written notice period for redemption of warrants								30 days
Stock price trigger for redemption of warrants (in dollars per share) | $ / shares								$ 21.00
Threshold trading days for redemption of warrants | D								20
Redemption period | D								30
Number of warrants per unit								1
Placement Warrants
Stockholders Equity [Line Items]
Number of outstanding warrants			136,250					136,250
Change in fair value of the warrants | $						0			0
Public Right
Stockholders Equity [Line Items]
Number of outstanding warrants			6,900,000					6,900,000
Number of shares per unit								1
Number of shares per right								1
Placement Rights
Stockholders Equity [Line Items]
Number of outstanding warrants			272,500					272,500
Merger agreement
Stockholders Equity [Line Items]
Merger and PIPE Financing shares - common stock								3,729,730
Merger agreement | Stockholders of NeuroRx
Stockholders Equity [Line Items]
Exchange Ratio	3.16	4.96
General and administrative
Stockholders Equity [Line Items]
Compensation expenses | $			$ 1,340,023			$ 64,604		$ 5,778,606	$ 182,073
Common Stock
Stockholders Equity [Line Items]
Merger and PIPE Financing shares - common stock			3,238,338			292,534		3,642,515	343,378
Issuance of common stock for exercise of warrants and Unit Purchase Options (in shares)			2,334,370					3,830,586
Proceeds from issuance of common stock | $			$ 31,134,816			$ 1,412,067		$ 39,624,175	$ 1,589,092
Awarded to employees as bonus for services provided						200,000		200,000
Common Stock | General and administrative
Stockholders Equity [Line Items]
Compensation expenses | $								$ 4,850,000
Legacy NeuroRx Preferred Stock | Convertible Series A Preferred Stock
Stockholders Equity [Line Items]
Preferred stock, shares authorized			1,000,000					1,000,000		1,000,000
Preferred stock, shares issued			1,000,000					1,000,000		1,000,000
Preferred stock, par value | $ / shares			$ 0.001					$ 0.001		$ 0.001
Preferred stock, conversion basis								one share of common stock for each preferred share
Convertible preferred stock, liquidation preference per share | $ / shares			$ 1.00					$ 1.00		$ 1.00
Number of shares outstanding	2,367,543
Shares issued upon conversion	7,480,836
Legacy NeuroRx Preferred Stock | Convertible Series B-1 Preferred Stock
Stockholders Equity [Line Items]
Preferred stock, shares authorized			1,050,695					1,050,695		1,050,695
Preferred stock, shares issued			1,050,695					1,050,695		1,050,695
Convertible preferred stock, liquidation preference per share | $ / shares			$ 7.58					$ 7.58		$ 7.58
Legacy NeuroRx Preferred Stock | Convertible Series B-1A Preferred Stock
Stockholders Equity [Line Items]
Preferred stock, shares authorized			316,848					316,848		316,848
Preferred stock, shares issued			316,848					316,848		316,848
Convertible preferred stock, liquidation preference per share | $ / shares			$ 6.82					$ 6.82		$ 6.82
Legacy NeuroRx Preferred Stock | Convertible Series B-2 Preferred Stock
Stockholders Equity [Line Items]
Preferred stock, shares authorized										100,000
Preferred stock, shares issued							4,167
Preferred stock, par value | $ / shares										$ 0.001
Preferred stock, conversion basis										one share of common stock for each share of B-2 Preferred Stock
Convertible preferred stock, liquidation preference per share | $ / shares										$ 12.00
Number of shares outstanding	4,167
Shares issued upon conversion	13,168